We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CRISPR THERAPTC (CRSP - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
CRISPR THERAPTC is one of 845 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CRSP's full-year earnings has moved 1.13% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that CRSP has returned about 65.46% since the start of the calendar year. In comparison, Medical companies have returned an average of 5.39%. This means that CRISPR THERAPTC is outperforming the sector as a whole this year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 341 individual stocks and currently sits at #92 in the Zacks Industry Rank. On average, stocks in this group have lost 10.85% this year, meaning that CRSP is performing better in terms of year-to-date returns.
CRSP will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CRISPR THERAPTC (CRSP - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
CRISPR THERAPTC is one of 845 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CRSP's full-year earnings has moved 1.13% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that CRSP has returned about 65.46% since the start of the calendar year. In comparison, Medical companies have returned an average of 5.39%. This means that CRISPR THERAPTC is outperforming the sector as a whole this year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 341 individual stocks and currently sits at #92 in the Zacks Industry Rank. On average, stocks in this group have lost 10.85% this year, meaning that CRSP is performing better in terms of year-to-date returns.
CRSP will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.